NEW YORK (GenomeWeb News) – Clinical lab organizations and a number of companies that develop and make molecular diagnostics have banded together to create a group to press for better government reimbursement while the US Centers for Medicare and Medicaid Services works to restructure its pricing plans.

The Coalition to Strengthen the Future of Molecular Diagnostics said last week that it has launched because CMS has been paying lower reimbursement rates while it conducts a review of its process for pricing these tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.